rs1131769 (5q31): Understanding Your Genotype and Cancer Research
rs1131769 is a single nucleotide polymorphism located on chromosome 5 at cytoband 5q31. Genome-wide association studies have identified it as a candidate locus associated with modest differences in cancer susceptibility across diverse ancestral groups. However, the evidence connecting rs1131769 to individual disease risk remains limited and exploratory, meaning it does not serve as a diagnostic marker.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| CC | Carriers of two C alleles exhibit the baseline statistical profile observed for this genotype in association studies. In population research, this genotype corresponds to standard reference risk levels for traits mapped to the 5q31 locus. It does not confer complete immunity to cancer or indicate a rare genetic vulnerability. | Informational |
| CT | Carriers of one C allele and one T allele possess a heterozygous genotype commonly found across global populations. In cross-ancestral GWAS literature, this status is associated with an incremental, modest statistical shift in cancer susceptibility odds. Because the effect size is very small, it does not hold diagnostic or predictive value on its own. | Informational |
| TT | Carriers of two T alleles have the homozygous alternative genotype at this locus. While epidemiological research links this pattern with modest statistical associations for specific cancer phenotypes in aggregate cohorts, it does not cause disease by itself. Having this genotype is a common population variation and does not require altered clinical intervention. | Higher attention |
Genomic Location and Variant Characteristics
The single nucleotide polymorphism rs1131769 resides on the long arm of human chromosome 5 in the 5q31 chromosomal region. In human genetics catalogs, this locus is evaluated both as an independent 5q31 association signal and in relationship to the cyclic dinucleotide-sensing gene STING1 (also known as TMEM173) and nearby loci such as CTNNA1. The variant typically represents an exchange between cytosine (C) and thymine (T) alleles. While some catalogs classify 5q31 risk signals as intergenic or non-coding regulatory marks, related molecular biology studies map rs1131769 to functional domains involved in innate immune signaling. Because chromosome 5q31 contains multiple regulatory elements, complex linkage disequilibrium structures, and neighboring genes, isolating the precise causal mechanism requires continuous fine-mapping and tissue-specific expression analyses.
Biological Mechanisms and the 5q31 Region
The genomic neighborhood around 5q31 plays a critical role in human immunity and structural cellular adhesion. STING1 (stimulator of interferon response cGAMP interactor 1) acts as a pivotal sensor of cytosolic cyclic dinucleotides and foreign or damaged DNA, orchestrating type I interferon release and innate antitumor immune surveillance. Functional and epidemiological studies indicate that variants in this region, including rs1131769 and its co-inherited markers, can correlate with immune response phenotypes or alter the baseline expression of nearby genes like catenin alpha 1 (CTNNA1). Because CTNNA1 is involved in actin filament binding and cell-cell adhesion, perturbations in this chromosomal region could theoretically influence tumor suppression and cellular architecture, though the exact physiological pathway remains an active focus of research.
What Population Association Studies Show
Cross-ancestral logistic-regression genome-wide association studies (GWAS) have characterized rs1131769 as an independent 5q31 risk signal for cancer susceptibility, including head and neck squamous cell carcinomas. Large-scale meta-analyses across European, Admixed American, African, and Asian ancestral cohorts have noted statistically significant associations, with odds ratios typically reflecting modest risk differences (often ranging between 1.10 and 1.25 per risk allele). Importantly, the overall evidence strength for rs1131769 is classified as limited. In statistical genetics, modest effect sizes observed across population cohorts reflect average epidemiologic associations rather than high-penetrance mutations. As such, having an associated allele does not signify that a person is doomed to develop malignancy.
Ancestry and Global Population Distribution
According to multi-ethnic reference panels such as the 1000 Genomes Project and the Genome Aggregation Database (gnomAD), rs1131769 is a common, polymorphic variant present in populations worldwide. Both the major and minor alleles are routinely observed across continental groups, including individuals of European, African, East Asian, South Asian, and Latino/Admixed descent. Because allele frequencies vary considerably between geographical ancestries due to historical human migration and drift, statistical studies must rigorously correct for population substructure. This natural, widespread variation reinforces the view that rs1131769 is an ancient common variant rather than an inherently damaging or rare monogenic defect.
Clinical Utility and What You Can Do
Currently, rs1131769 has no direct clinical application, and professional medical genetics guidelines do not recommend screening for it in routine clinical care. It cannot be used to diagnose any disease, predict the onset of cancer, or formulate a medical prognosis. Direct-to-consumer genetic panels occasionally report this variant, but an associated statistical finding should not be interpreted as a medical diagnosis. Instead of focusing on single common variants, individuals concerned about cancer risk are advised to maintain evidence-based lifestyle habits—such as avoiding tobacco, limiting alcohol, eating a balanced diet, and attending standard recommended health screenings—and to discuss personal or family medical histories with a qualified physician or genetic counselor.
How common is this variant?
Polymorphic across diverse continental populations in the 1000 Genomes Project and gnomAD, with both alleles commonly observed across European, African, Asian, and Admixed American ancestries.
Frequently asked questions
Does having the rs1131769 risk allele mean I will get cancer?
No. Carrying one or two copies of an associated allele at rs1131769 reflects only a slight statistical association detected in large epidemiological datasets. Common variants have tiny individual effect sizes and do not dictate personal disease onset, which depends far more on overall lifestyle, age, environment, and complex family history.
What gene is rs1131769 located in?
Depending on the genomic build and annotation database, rs1131769 sits at chromosome 5q31 and is closely linked with both the STING1 (TMEM173) and CTNNA1 loci. Some catalogs classify the 5q31 lead signals as intergenic or regulatory, while biological studies continue to assess its potential direct coding or regulatory impacts.
Can rs1131769 be used to guide cancer treatment or medications?
No, rs1131769 is not an actionable pharmacogenomic marker. Professional organizations such as CPIC and PharmGKB have not established guidelines linking this variant to drug dosing or therapeutic selection. Any questions regarding medications should always be reviewed directly with a physician or pharmacist.
Why is the evidence strength for rs1131769 classified as limited?
The evidence is considered limited because the variant was discovered through population-level genome-wide association studies that demonstrate statistical correlations rather than proven biological causation. Furthermore, functional biological validation across diverse tissues remains incomplete, meaning clinical relevance cannot be confirmed.
Sources & further reading
Educational information only, last refreshed 9/6/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1131769?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29